Get started
Author

Rasima Cehic

Observed name: R. Cehic
Observed institution: Northwestern University
OpenAlex ID: A5017516375
A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas
2016 · M. Agulnik, R.L.B. Costa, et al. · Annals of Oncology · 30
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
2021 · Mark Agulnik, Brian Schulte, et al. · European Journal of Cancer · 28
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas
2021 · Brian Schulte, Nisha Mohindra, et al. · British Journal of Cancer · 19
PDF
A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
2018 · Mark Agulnik, Nisha Anjali Mohindra, et al. · Journal of Clinical Oncology · 5
A phase II study of tivozanib in patients with metastatic and non-resectable soft tissue sarcomas.
2015 · Mark Agulnik, Mohammed M. Milhem, et al. · Journal of Clinical Oncology · 2
A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas.
2014 · Lauren Elizabeth Nye, Ariel Polish, et al. · Journal of Clinical Oncology
Works count: 6
Citation count: 84
H-index: 4
I10-index: 3
Year
Topic
Type